- Home
- CUE vs TORO Comparison
CUE vs TORO Comparison
Compare CUE & TORO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | TORO |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | Cyprus |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 173.8M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CUE | TORO |
|---|---|---|
| Price | $25.12 | $5.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | ★ 71.2K | 48.6K |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 36.86% |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $2.10 |
| 52 Week High | $41.42 | $8.50 |
Technical Indicators
Market Signals| Indicator | CUE | TORO |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 51.05 |
| Support Level | $0.30 | $4.96 |
| Resistance Level | $32.60 | $5.85 |
| Average True Range (ATR) | 3.67 | 0.21 |
| MACD | -0.57 | 0.00 |
| Stochastic Oscillator | 42.10 | 68.42 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.